Simulations Plus, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Aug 31, 2025	FY2024 12 months to Aug 31, 2024	FY2023 12 months to Aug 31, 2023	FY2022 12 months to Aug 31, 2022	FY2021 12 months to Aug 31, 2021
Cash flows from operating activities
Net (loss) income
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization
Change in fair value of contingent consideration
Discharge of holdback obligation related to Immunetrics acquisition
Amortization of investment discounts
Stock-based compensation
Deferred income taxes
Loss from disposal of assets
Impairments
Currency translation adjustments
(Increase) decrease in
Accounts receivable
Revenues in excess of billings
Prepaid income taxes
Prepaid expenses and other assets

Increase (decrease) in
Accounts payable
Accrued payroll and other expenses
Billings in excess of revenues
Other liabilities
Accrued income taxes
Deferred revenue

Net cash provided by operating activities
Cash flows from investing activities
Purchases of property and equipment
Purchases of intellectual property
Purchase of short-term investments
Proceeds from maturities of short-term investments
Proceeds from sales of investments
Issuance of promissory note
Purchased intangibles
Cash received in acquisition
Business acquisition, net of cash acquired
Net working capital & excess cash settlement - Pro-ficiency acquisition
Capitalized computer software development costs
Net cash used in investing activities

Cash flows from financing activities
Payment of dividends
Payments on contracts payable
Proceeds from the exercise of stock options
Proceeds from follow-on public offering, net
Repurchase and retirement of common shares
Net cash used in financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosures of cash flow information
Income taxes paid
Non-Cash Investing and Financing Activities
Stock issued for acquisition of Lixoft
Measurement period adjustments (See Note 2)
Creation of contract liabilities from acquisition of subsidiaries
Right of use assets capitalized

Comments